Fady Botros
Associate Vice President, Cardiometabolic Health Clinical Research Design Eli Lilly
Seminars
Wednesday 15th April 2026
Unlocking Synergistic Efficacy Using GLP-1 Combinations to Halt Cardiorenal Progression in Chronic Kidney Disease
9:00 am
- Understanding the rationale and clinical evidence for combining GLP-1 Receptor Agonists (GLP-1 RAs) with complementary agents to achieve a synergistic blockade of the complex metabolic, hemodynamic, and inflammatory pathways that drive the progression of CKD and its cardiovascular sequelae
- Recognizing how these combination strategies can be personalized for patients across the CKD spectrum, from early-stage albuminuria to advanced disease, by optimizing the balance of glucose control, weight loss, blood pressure management, and direct kidney protection to maximize the reduction in Major Adverse Kidney Events (MAKE) and associated Major Adverse Cardiovascular Events (MACE).
- Grasping the emerging role of next-generation multi-agonists (e.g., GIP/GLP-1/ Glucagon) and their combinations with non-hormonal agents in tackling the high unmet need in CKD, specifically focusing on their potential to induce substantial weight loss while providing additive renoprotective and anti inflammatory benefits superior to current dual-agent regimens
